



Advicenne announces the opening of a safeguard proceedings to restructure its financial liabilities and finalize the extension of its cash runway

- **A proactive initiative to restructure the Company's debt**
- **A protective framework that allows for the continuation of commercial, clinical, and regulatory activities, as well as discussions with potential partners**
- **A financing plan currently being finalized to extend the cash runway through the end of Q1 2027**

Paris, France, May 5, 2026 – 9.00PM (CET) – Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announces today that the Paris Commercial Court granted its request to initiate a safeguard procedure to restructure its debt within a protective legal framework. As such, the Company's liabilities incurred prior to the decision are frozen until the end of the proceedings. During this period, the Company will continue its operations under the legal protection afforded by the safeguard proceedings. At the same time, Advicenne is finalizing a financing plan with existing and future shareholders to extend its cash runway through the end of Q1 2027

To date, the Company's debt stands at €29.3 million, including €16.5 million in debt to the European Investment Bank (EIB), €2.4 million in State-Guaranteed Loans (PGE) and 10.3 million euros to the French government. The latter is linked to the implementation of the reform regarding early access to innovative medicines in July 2021 (AAP clawback) requiring the Company to remit up to 80% of its revenue generated in France. There is no other social or fiscal debt.

Advicenne has been engaged in amicable negotiations for several months and has made significant progress in these discussions. Nevertheless, to expedite the process and achieve a significant reduction in its debt, Advicenne has decided to file for safeguard proceedings, which will protect its interests and those of its shareholders.

This proactive initiative is part of the commitment by Advicenne's management and its major shareholders to create the most favorable conditions for the continued commercial success of Sibnaya[®] in Europe and the Middle East; to finalize the registration of Sibnaya[®] for distal renal tubular acidosis (dRTA) in the United States, expected by September 3, 2026, at the latest; and to establish strategic partnerships.

As part of the proceedings, the Paris Commercial Court has appointed SELARL AJUP, represented by Maître Paul-Henri Audras, as the judicial administrator tasked with overseeing mission, as well as SELAFA MJA, represented by Maître Frédérique Levy, as legal representative.

The Company will keep the market regularly informed of developments in the proceedings and, more generally, of Advicenne's financial situation.



The Company is hosting its first webinar for shareholders, in French, on Wednesday May 6, 2026 at 5:45 p.m., which can be accessed via the following link:

[ADVICENNE WEBCAST](#)

This webcast will be recorded and posted on Advicenne's website.

* *
.*

ABOUT THE SAFEGUARD PROCEEDINGS

The safeguard proceedings can last up to twelve months and protect companies that are not in cessation of payments, enabling them to resolve their difficulties and continue their activities.

ABOUT ADVICENNE

Advicenne (Euronext Growth Paris ALDVI - FR0013296746) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnaya[®] (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU and GB. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022.

For additional information, see: <https://advicenne.com/>

CONTACTS

Advicenne

Didier Laurens, Directeur Général
+33 (0) 1 87 44 40 17
Email : investors@advicenne.com

Maarc – Media relations

Bruno Arabian
+33 (0)6 87 88 47 26
Email : bruno.arabian@maarc.fr



Disclaimer

This press release contains certain forward-looking statements concerning Advicenne group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Advicenne considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2025 Universal Registration Document filed with the French financial market authority on April 24, 2026 (a copy of which is available on www.advicenne.com) and to the development of economic conditions, financial markets and the markets in which Advicenne operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Advicenne or not currently considered material by Advicenne. The occurrence of all or part of such risks could cause actual results, financial 6/6 conditions, performance, or achievements of Advicenne to be materially different from such forward-looking statements. Advicenne expressly declines any obligation to update such forward-looking statements.